BOW(SZ:300070) Chang Jiang Shang Bao·2025-07-17 23:31Core Viewpoint - The founder and former chairman of BWS (碧水源), Wen Jianping, faces significant challenges following his resignation and ongoing legal issues, which may impact the company's future performance and governance [1][10]. Company Performance - BWS reported declining revenues and profits in recent quarters, with 2024 revenue at 85.49 billion yuan, down 4.51% year-on-year, and a net profit of 58.59 million yuan, down 92.34% [2][15]. - In the first quarter of 2025, BWS's revenue was 15.91 billion yuan, a decrease of 12.65% year-on-year, with a net profit of 60.04 million yuan, down 34.29% [2][16]. Financial Health - As of the first quarter of 2025, BWS's accounts receivable reached 124.87 billion yuan, indicating potential cash flow issues [3][17]. - The company's debt-to-asset ratio has been increasing, reaching 62.63% by the end of the first quarter of 2025, up from 60.53% in 2024 [3][16]. Shareholder Actions - Wen Jianping's shares, totaling 37.45 million, are set for judicial auction, valued at approximately 169 million yuan based on a share price of 4.51 yuan [4][5]. - Wen Jianping has reduced his holdings significantly, cashing out approximately 1.4 billion yuan from 2020 to 2023 [9]. Company History and Changes - BWS was founded by Wen Jianping in 2001 and became a leader in membrane treatment technology, going public in 2010 [6][14]. - The company underwent a mixed-ownership reform in 2019, leading to a change in control [7][8].